Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
To study if decitabine can help to control Myelodysplastic Syndrome (MDS) in patients who
have failed on therapy with azacytidine, the current standard of therapy.